Sixteen patients across nine families, scattered from the United Kingdom to Spain to Oman to Egypt, finally have answers to questions that have haunted their parents for years: why their children's brains were shrinking, why seizures wouldn't stop, why development was slipping away. A multinational research team has identified mutations in a single gene—BORCS5—as the root cause of a spectrum of severe neurological disorders that ranges from devastating prenatal brain malformations to progressive childhood neurodegeneration, according to a study published in the Journal of Clinical Investigation.
The discovery matters because these children were living medical mysteries. Many had unexplained epileptic encephalopathy or early-onset movement disorders with no diagnosis, no clear path forward. Now, researchers led by Dr. Niccolò Mencacci at Northwestern University can explain why their neurons are failing: the BORCS5 gene, which normally acts as a master regulator of lysosomes—the cellular structures that break down and recycle waste—isn't working properly. In neurons, which maintain delicate transport systems along axons, this failure is particularly catastrophic.
The clinical picture varies dramatically depending on which mutations are present. Patients with complete loss of the BORCS5 protein face the gravest outcomes: brain malformations, abnormal fetal movements, and a condition called neuroaxonal dystrophy that is often fatal before birth. Those with partially functioning mutations navigate a different, though still profound, trajectory—living with progressive epilepsy, movement problems, and intellectual disability, their developmental milestones slipping away over time. Brain scans reveal the toll: widespread abnormalities including hypomyelination, structural defects in the corpus callosum, and progressive brain atrophy that documents ongoing neurodegeneration.
The research began with genetic sequencing. Multiple independent teams across different countries, working with families they didn't initially know were connected, each identified the same gene: BORCS5. It was convergence—the hallmark of discovery. To understand how mutations caused disease, researchers engineered zebrafish lacking the gene. These animals developed smaller brains, motor impairments, and increased seizure susceptibility, closely mirroring the human condition. When they studied human neurons grown from stem cells, the mechanism became clearer. Severe mutations caused lysosomes to cluster abnormally and fail to travel along axons. Milder mutations took a different path: they didn't disrupt lysosome distribution but instead broke the machinery that breaks down cellular waste. Both pathways led to the same place: neurological devastation, just expressed differently.
What makes this discovery extend beyond these 16 patients is the window it opens into more common diseases. The enzymes BORCS5 helps maintain have been implicated in Parkinson's disease and other neurodegenerative conditions affecting millions. Understanding how BORCS5 regulates these enzymes could illuminate mechanisms central to diseases far more prevalent than this rare genetic condition.
Dr. Mencacci and his collaborators are now investigating how BORCS5 controls lysosomal activity at the molecular level, searching for therapeutic angles that might one day slow or halt disease progression. For the families who finally have answers, this research represents something more immediate: validation that their children's conditions were real, rooted in biology, and worthy of the world's scientific attention.